This study investigates pancreatic cancer. It uses a method called RNA expression profiling to guide treatment decisions based on the cancer subtype.
The focus is on evaluating the effectiveness of tailored chemotherapy treatments for different pancreatic cancer subtypes. Researchers are interested in understanding how these treatments work for each subtype.
- Who can participate: Adults 18 years or older with resectable or borderline resectable pancreatic adenocarcinoma may participate. Participants must have adequate organ function.
- Study details: Participants will receive a specific chemotherapy regimen based on their cancer subtype. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand